Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

Recruiting now

Conditions studied: Sickle Cell Disease

In brief

The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that do not develop alloimmunization. This may help us to create more targeted therapeutic interventions, which may improve the health of alloimmune responders.

Key facts

Study ID

NCT06944067

Run by

National Human Genome Research Institute (NHGRI)

People needed

50

Starts

2025-06-24

Expected to finish

2030-04-10

Last updated by the study team

2026-05-27

Who can join

Age: 2 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• An individual who meets any the following criteria will be excluded from participation in this study:
• Impaired decision-making capability, with or without a legally authorized representative
• History of transplant (e.g., organ, bone marrow, stem cell)
• Taking immunosuppressive medications at time of enrollment
• Confirmed pregnancy

Where it is running

• National Institutes of Health Clinical Center — Bethesda, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.